Medication adherence of oral endocrine therapy in breast cancer patients in a large academic medical center
Kelvin Lu(Methodist Hospital), Meghana V. Trivedi(University of Houston), Rutugandha Paranjpe(Merck & Co., Inc., Rahway, NJ, USA (United States)), Susan Abughosh(University of Houston), Uzoamaka Abajue(Methodist Hospital), Hanna Zaghloul(Houston Methodist), Grace Hwang(University of Houston), Carine Opsomer(Methodist Hospital)
Cited by 0
Related Papers
Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer
|Clinical Cancer Research|2013|273
Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize
|Cancer Research|2018|221
Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications
|Breast Care|2013|200
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer
|Proceedings of the National Academy of Sciences|2016|185
The changing role of ER in endocrine resistance
|The Breast|2015|133